Sign inJoin waitlistJoin the waitlist

ND

Nabil Dib

Affiliate Professor · Creighton University School of Medicine

Credentials: · · · · · ·

History

Creighton University School of Medicine
Present

Cardiovascular Disease
1998–2001
Harvard School of Public Health
1999
Harvard Medical School
1997–1998
Tufts University
1992–1994
Internal Medicine
Boston University
1991–1992
1990–1991
DAMASCUS UNIV, DAMASCUS
1982–1986

Research

A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction
Journal of the American College of Cardiology · 2009 · 1,030 citations
Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction
Science Translational Medicine · 2013 · 349 citations
Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC)
Journal of the American College of Cardiology · 2015 · 329 citations

ED
Edward Diethrich
7 papers
FM
Francois-Pierre Mongeon
6 papers
Anthony DeMaria
5 papers
Dean Kereiakes
5 papers
Timothy Henry
5 papers
IB
Ismail Bouhout
4 papers
Martin Leon
4 papers
Alexander Opotowsky
3 papers
Alexandra Lansky
3 papers
Ali Zaidi
3 papers
BM
Brent McLaurin
3 papers
CB
Craig Broberg
3 papers

Clinical trials

Coronary Flow Reserve Following Orbital Atherectomy
Principal investigator · Completed
Abbott Medical Devices
2015–2016
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
Principal investigator · Withdrawn · Phase 2
Stemedica Cell Technologies, Inc.
2013–2017
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2030
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2028